Prevalence and factors associated with a prolonged QTc interval in a cohort of asymptomatic HIV-infected patients

AIDS Research and Human Retroviruses

Volumn 29, Issue 9, 2013, Pages 1195-1198

  Moreno, Tamara ^a   Pérez, Isabel ^a   Isasti, Guillermo ^a   Cabrera, Fernando ^a   Santos, Jesús ^a,b   Palacios, Rosario ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina IBIMA Plataforma Bionand   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ASYMPTOMATIC INFECTION; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE DURATION; ELECTROCARDIOGRAM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QT PROLONGATION; QUESTIONNAIRE; RISK ASSESSMENT; TRANSTHORACIC ECHOCARDIOGRAPHY; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; LONG QT SYNDROME; MALE; MIDDLE AGED; OLIGOPEPTIDES; PREVALENCE; PYRIDINES; QUESTIONNAIRES; RISK FACTORS; VIRAL LOAD;

EID: 84882986260     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0061     Document Type: Article

References (28)

1. Mocroft A, Ledergerber B, Katlama C, et al. and the Euro-SIDA Study Group: Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003; 362:22-29.
2. Ho JE and Hsue PY: Cardiovascular manifestations of HIV infection. Heart 2009;95:1193-1202.
3. Crow RS, Prineas RJ, Hannan PJ, Grandits G, and Blackburn H: Prognostic associations of Minnesota Code serial electrocardiographic change classification with coronary heart disease mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol 1997;80:138-144.
4. Sutherland SE, Gazes PC, Keil JE, Gilbert GE, and Knapp RG: Electrocardiographic abnormalities and 30-year mortality among white and black men of the Charleston Heart study. Circulation 1993;88:2685-2692.
5. Singh M, Arora R, and Jawad E: HIV protease inhibitors induced prolongation of the QT interval: Electrophysiology and clinical implications. Am J Ther 2010;17:e193-201.
6. Anson BD, Weaver JG, Ackerman MJ, et al.: Blockade of HERG channels by HIV protease inhibitors. Lancet 2005;365: 682-686.
7. Expert Panel on Detection, Evaluation, and Treatment of high blood cholesterol in adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 2001;285:2486-2497.
8. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1998;21: 5S-19S.
9. Joint National Committee: The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157: 2413-2446.
10. Moss AJ: Long QT syndome. JAMA 2003;289:2041-2044.
11. Douglas PS, M. DeCara J, Devereux RB, et al.: Echocardiographic Imaging in Clinical Trials: American Society of Echocardiography Standards for Echocardiography Core Laboratories. J Am Soc Echocardiogr 2009;22:755-765.
12. Isasti G, Pérez I, Moreno T, Cabrera F, Palacios R, and Santos J: Echocardiographic abnormalities and associated factors in a cohort of asymptomatic HIV-infected patients. AIDS Res Hum Retroviruses 2013;29:20-24.
13. Kocheril AG, Bokhari SA, Batsford WP, and Sinusas AJ: Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol 1997;20: 2810-2816.
14. Ravens U and Cerbai E: Role of potassium currents in cardiac arrhythmias. Europace 2008;10:1133-1137.
15. Soliman E, Prineas R, Roediger M, et al.: Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: Results from the Strategies for Management of Antiretroviral Therapy study. J Electrocardiol 2011;44: 779-785.
16. Sani MU and Okeahialam BN: QTc interval prolongation in patients with HIV and AIDS. J Natl Med Assoc 2005;97: 1657-1661.
17. Qaqa AY, Shaaban H, DeBari VA, et al.: Viral load and CD4 cell count as risk factors for prolonged QT interval in HIV infected subjects: A cohort-nested casecontrol study in an outpatient population. Cardiology 2010;117:105-111.
18. Shavadia J, Shah R, Yonga G, Patel R, Stebbing J, and Nelson M: The influence of antiretroviral therapy on the QTc interval in an African cohort. Clin Infect Dis 2012;54:448-449.
19. Khan IA: Long QT syndrome: Diagnosis and management. Am Heart J 2002;143:7-14.
20. Aggarwal P, Sharma A, Bhardwaj R, and Raina R: Myocardial dysfunction in human immunodeficiency virus infection: An echocardiographic study. J Assoc Physicians India 2009;57:745-746.
21. Schuster I, Thöni GF, Edérhy S, et al.: Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy. Am J Cardiol 2008; 101:1213-1217.
22. Morris A, Ginkgo MR, George MP, et al.: Cardiopulmonary function in individuals with HIV infection in the antiretroviral therapy era. AIDS 2012;26:731-740.
23. Liang KP, Myasoedova E, Crowson CS, et al.: Increased prevalence of diastolic dysfunction in rheumatoid arthritis. Ann Rheum Dis 2010;69:1665-1670.
24. Chinello P, Lisena FP, Angeletti C, Boumis E, Papetti F, and Petrosillo N: Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients. J Infect 2007;54:597-602.
25. Damle B, Fossrer C, Ito K, et al.: Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: A thorough QYT study. J Clin Pharmacol 2009;49:291-300.
26. Ly T and Ruiz ME: Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin Infect Dis 2007;44:67-68.
27. Soliman EZ, Lundgren JD, Roediger MP, et al.: INSIGHT SMART Study Group: Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS 2011;25:367-377.
28. Gallagher DP, Kieran J, Sheehan G, Lambert J, Mahon N, and Mallon PW: Ritonavir boosted atazanavir, methadone, and ventricular tachycardia: 2 cases reports. Clin Infect Dis 2008;47:e36-38.